Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells

Cytotherapy

Volumn 16, Issue 2, 2014, Pages 278-284

  Yang, Bo ^a   Wang, Ji ^b   Cai, Li Li ^a   Zhu, Hong Li ^a   Yu, Rui Li ^a   Chi, Xiao Hua ^c   Lu, Xue Chun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NAVY GENERAL HOSPITAL   (China)

^c Second Artillery General Hospital   (China)

Author keywords

Cancer; Chemotherapy; Cytokine induced killer cells; Immunotherapy; Plasmacytoma

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE; IBANDRONIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; SYNDECAN 1; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; AGED; ARTICLE; BONE BIOPSY; BONE LESION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONJUNCTIVITIS; CYTOKINE INDUCED KILLER CELL INFUSION; DISEASE SEVERITY; DIZZINESS; EDEMA; EVENING DOSAGE; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LEUKOPENIA; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE SOLITARY PLASMACYTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMATITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

CANCER; CHEMOTHERAPY; CYTOKINE-INDUCED KILLER CELLS; IMMUNOTHERAPY; PLASMACYTOMA;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CANCER VACCINES; CYTOKINE-INDUCED KILLER CELLS; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MALE; PLASMACYTOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 84892453817     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.11.001     Document Type: Article

References (18)

1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757. International Myeloma Working Group.
2. Lokhorst H.M., Schattenberg A., Cornelissen J.J., Thomas L.L., Verdonck L.F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211.
3. Lokhorst H.M., Schattenberg A., Cornelissen J.J., van Oers M.H., Fibbe W., Russell I., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. JClin Oncol 2000, 18:3031-3037.
4. Verdonck L.F., Petersen E.J., Lokhorst H.M., Nieuwenhuis H.K., Dekker A.W., Tilanus M.G., et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998, 22:1057-1063.
5. Salama M., Nevill T., Marcellus D., Parker P., Johnson M., Kirk A., et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000, 26:1179-1184.
6. Cook G., Campbell J.D. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev 1999, 13:151-162.
7. Kwak L.W., Taub D.D., Duffey P.L., Bensinger W.I., Bryant E.M., Reynolds C.W., et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995, 345:1016-1020.
8. Li Y., Bendandi M., Deng Y., Dunbar C., Munshi N., Jagannath S., et al. Tumour-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood 2000, 96:2828-2833.
9. Harrison S.J., Cook G., Nibbs R.J., Prince H.M. Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Rev Anticancer Ther 2006, 6:1769-1785.
10. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the International Registry on CIK Cells (IRCC). JCancer Res Clin Oncol 2011, 137:305-310.
11. Li X.D., Xu B., Wu J., Ji M., Xu B.H., Jiang J.T., et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012, 14:102-108.
12. Lu X.C., Yang B., Yu R.L., Chi X.H., Tuo S., Tuo C.W., et al. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys 2012, 62:257-265.
13. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679-1687.
14. Leemhuis T., Wells S., Scheffold C., Edinger M., Negrin R.S. APhase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187.
15. Olioso P., Giancola R., Di Riti M., Contento A., Accorsi P., Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009, 27:130-139.
16. Yang B., Lu X.C., Yu R.L., Chi X.H., Liu Y., Wang Y., et al. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 2012, 30:115-122.
17. Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007, 138:563-579.
18. Harrison S.J., Franklin I.M., Campbell J.D. Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. Leuk Lymphoma 2008, 49:2272-2283.